$heff's $tation of $tocks & $olid DD

[nywest329]

AMRN- from a Yahoo post about Leerink

AMRN

Stock weakness unwarranted


We believe yesterday afternoon’s stock weakness was triggered by a retail seller, who had to sell at the market, which triggered some sell stops for other investors.
We don’t believe it is anything fundamental.

? Thestreet.com and a competitor are spinning a recent “orange book discussion” on 6/22 posted on the FDA website on 6/27 among senior FDA officials, the company, their attorneys, and Kurt Karst negatively … although everyone we have spoken with agrees with us that it is probably positive.
? There isn’t any more information but this should be a very good sign for approval and potentially having a tighter patent thicket on FDA approval, even if all of these patents are granted after FDA approval.
http://www.fda.gov/NewsEvents/MeetingsCo...

Investors are highly focused on whether AMR101 will be granted NCE status, and we continue to believe that AMRN may benefit from a “presumption in favor policy” at the FDA.
… AMR101 is a natural product like heparins and pancreatic enzymes which have been granted NCE status.
… Interestingly, Kurt Karst is a top FDA lawyer who points this out in his blog:
http://www.fdalawblog.net/fda_law_blog_h...

Meanwhile, MEDACorp patent specialists tell us that “Document Verification” on the PAIR website means that the ‘145 patent will receive a notice of allowance very soon, as in another day or two.
:: This is an incremental positive since ‘145 claims are geared towards the TG lowering findings in the MARINE study, which they stripped out of the ‘889 method of use patent in order to get the ‘885 patent issued.
:: Now they should have all of the claims they originally sought, despite the examiner’s difficulty along the way.

Date Transaction Description
07-05-2012 Document Verification
07-05-2012 Email Notification
07-05-2012 Change in Power of Attorney (May Include Associate POA)

Reiterate Outperform and buyers on AMRN weakness.